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Pathogenesis in kala-azar is associated with depressed cellular immunity and significant elevation of
antileishmanial antibodies. Since these antibodies are present even after cure, analysis of the parasite-specific
isotypes and immunoglobulin G (IgG) subclasses in kala-azar patients may shed new light on the immune
responses during progression and resolution of infection. Using leishmanial membrane antigenic extracts, we
investigated the relative levels of specific IgG, IgM, IgA, IgE, and IgG subclasses in Indian kala-azar patient
sera during disease, drug resistance, and cure. Acute-phase sera showed strong stimulation of IgG, followed by
IgE and IgM and lastly by IgA antibodies. IgG subclass analysis revealed expression of all of the subclasses,
with a predominance of IgG1 during disease. Following sodium stibogluconate (SAG) resistance, the levels of
IgG, IgM, IgE, and IgG4 remained constant, while there was a decrease in the titers of IgG2 and IgG3. In
contrast, a significant (2.2-fold) increase in IgG1 was observed in these individuals. Cure, in both SAG-
responsive and unresponsive patients, correlated with a decline in the levels of IgG, IgM, IgE, and all of the
IgG subclasses. The stimulation of IgG1 and the persistence, most importantly, of IgE and IgG4 following drug
resistance, along with a decline in IgE, IgG4, and IgG1 with cure, demonstrate the potential of these isotypes
as possible markers for monitoring effective treatment in kala-azar.
Human visceral leishmaniasis (VL), or kala-azar, a systemic
fatal disease, is caused by Leishmania donovani, an intracellu-
lar protozoan parasite that infects and multiplies in the mac-
rophages of the spleen, liver, bone marrow, and lymph nodes.
The disease is associated with severe immunosuppression as
evidenced by the failure to respond to L. donovani antigens in
terms of delayed-type hypersensitivity, lymphoproliferation,
and interleukin-2 (IL-2) and gamma interferon (IFN-g) pro-
duction in vitro (13, 15, 37, 40). Enhanced induction of IL-10
and/or IL-4 mRNA in tissues and elevated levels of IL-4,
IL-10, and IgE over IFN-g in serum (20, 26, 28, 46, 48) suggest
that a dominant Th2 response suppresses the activity of Th1
during disease. With successful drug therapy, T-cell prolifera-
tion and IL-2 and IFN-g production in response to Leishmania
antigen are restored (13, 40). Cured individuals, however, show
Leishmania-reactive T cells with Th1- and Th2-type lympho-
kines coexisting after infection (7, 26, 27). Thus, the heteroge-
neous set of cytokine responses provoked by kala-azar during
disease and resolution of infection reflects a complex Th1-Th2
cell picture that is difficult to delineate for indicators of clinical
improvement.
VL is also marked by high levels of Leishmania-specific
antibodies (10, 34) which appear soon after infection and be-
fore the development of cellular immunologic abnormalities.
While the antibody titers in kala-azar have been exploited for
specific diagnosis, their role in resolution of disease and pro-
tective immunity is largely unknown. It is, however, evident
that resistance in a large population of individuals residing in
areas of endemicity is detectable only by the development of
specific antibodies and/or T-cell response to leishmanial anti-
gens (17, 29, 40). In our attempts to induce protection against
L. donovani infection in BALB/c mice, we have demonstrated
the involvement of cell-mediated and humoral immune re-
sponses in resistance against the disease (2, 4). Analysis of the
immunoglobulin G (IgG) subclasses revealed preferential
stimulation of IgG1 in infected mice and of IgG2a and IgG2b
in protected mice (2, 3). A study of Leishmania membrane
antigen (LAg)-specific Ig isotypes in Indian kala-azar patients
revealed the elevation of IgG, IgM, IgE, and IgG subclass
antibodies, with IgG3 being specifically associated with this
disease (5). In this study, we report the LAg-specific Ig isotypes
and IgG subclasses in the sera of kala-azar patients during
active disease, drug unresponsiveness, and successful cure, to
establish a correlation of these isotypes with progression and
resolution of infection. These observations may have impor-
tant implications for vaccine development as well as noninva-
sive assessment of the success of treatment of visceral leish-
maniasis. Since resistance to pentavalent antimonials, the
mainstay of VL chemotherapy, is on the rise, especially in India
(25, 46), the prediction of clinical relapse would be desired.
MATERIALS AND METHODS
Study subjects. The subjects of the present investigation were 5- to 70-year-old
VL patients (n 5 15) living in areas of eastern India, where kala-azar is endemic.
The patients (5 females and 10 males) were admitted to the School of Tropical
Medicine, Calcutta, India. Diagnosis of the disease and drug unresponsiveness
were confirmed parasitologically by the presence of Leishmania amastigotes in
spleen and/or bone marrow aspirates. Blood was obtained after diagnosis, before
the initiation of chemotherapy, posttreatment, and after cure. Treatment with 20
injections of sodium stibogluconate (SAG), the first-line drug (20 mg/kg of body
weight), led to successful cure in 10 patients, whereas five failed to respond to
SAG and were retreated with the second-line drug, amphotericin B (seven
injections; 1 mg/kg of body weight). Serum samples were taken from each of the
15 patients at least twice: on day 0 (i.e., before initiation of therapy) and 50 days
after successful treatment or 45 days after unsuccessful treatment with SAG.
Samples from the latter five patients were taken again at 75 days following
* Corresponding author. Mailing address: Indian Institute of Chemi-
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successful treatment with amphotericin B. A total of 35 different samples ob-
tained were studied in two groups. All patients had given informed consent to
participate in this study.
Antigen preparation. L. donovani AG83, originally isolated from an Indian
kala-azar patient, was cultured in vitro for antigen preparation as described
earlier (2). Briefly, stationary-phase promastigotes, harvested after the third or
fourth passage, were washed four times in ice-cold 0.02 M phosphate-buffered
saline, pH 7.2 (PBS), and suspended at a concentration of 1.0 g of cell pellet (ca.
5 3 1010 stationary-phase promastigotes) in 50 ml of cold 5 mM Tris-HCl buffer,
pH 7.6. The suspension was vortexed six times for 2 min each on ice with 10-min
intervals in between and centrifuged at 2,310 3 g for 10 min. The crude ghost
membrane pellet thus obtained was resuspended in 10 ml of the same Tris buffer
and sonicated three times for 1 min each on ice in an ultrasonicator. The
suspension was finally centrifuged at 4,390 3 g for 30 min, and the supernatant
containing the LAg was harvested and stored in aliquots at 270°C until use. The
amount of protein obtained from 1.0 g of cell pellet, as assayed by the method of
Lowry et al. (31), was 16 mg.
ELISA for parasite-specific Igs. Enzyme-linked immunosorbent assay
(ELISA) of IgG, IgM, IgA, IgE, and IgG subclass antibodies to LAg was carried
out on polystyrene round-bottom microtiter plates (Tarsons) as described earlier
(5). LAg extracted from L. donovani was applied to the plates at 20 mg/ml in 0.02
M phosphate buffer (pH 7.5) and incubated at 4°C overnight. After the plates
were washed three times with PBS supplemented with 0.05% Tween 20, excess
reactive sites were blocked with 1% bovine serum albumin for 3 h at room
temperature, washed as before, and subsequently incubated overnight at 4°C
with the kala-azar sera serially diluted in PBS containing 1% bovine serum
albumin. After washing, peroxidase-conjugated goat polyclonal antibodies di-
rected against human IgG, IgM, IgA, and IgE (Sigma Immunochemicals, St.
Louis, Mo.) were applied at a 1:5,000 dilution in PBS for 3 h at room temper-
ature. After four washes, o-phenylenediamine dihydrochloride was applied as an
enzyme substrate for 45 min, and the optical density was read at 492 nm in an
ELISA reader.
For the determination of human IgG subclass antibodies, the LAg-washed
wells incubated with serially diluted kala-azar sera were treated with mouse
anti-human IgG subclass-restricted monoclonal antibodies (Sigma Immuno-
chemicals) at a 1:3,000 dilution for 3 h at room temperature. After three washes,
peroxidase-conjugated goat anti-mouse IgG (Sigma Immunochemicals) was ap-
plied at a 1:5,000 dilution overnight at 4°C. The color reaction was carried out as
described above, and the optical density was read at 492 nm. Titers were deter-
mined from the extensive titration of each serum sample as the dilution of serum
required to reach half-maximal absorbance (A492 5 1.0).
Western blot analysis. After sodium dodecyl sulfate–10% polyacrylamide gel
electrophoresis, the LAg was electrophoretically transferred to nitrocellulose by
using a Transblot apparatus (Bio-Rad Laboratories). Immunoblot assays were
performed by the method of Rolland-Burger et al. (38) with slight modifications.
The blot was blocked overnight in 100 mM Tris-buffered saline (pH 7.6) con-
taining 0.1% Tween 20 (T-20) (8), washed once with 0.05% T-20 in Tris-buffered
saline (washing buffer), and incubated for 1 h with kala-azar acute-phase, SAG-
resistant, or convalescent-phase serum. Acute-phase and SAG-resistant sera
were diluted at 1:500, and convalescent-phase sera were diluted at 1:100, in
washing buffer. The blots were then washed three times for 20 min each and
incubated for 1 h with 1:500-diluted peroxidase-conjugated goat anti-human IgG
(Sigma Immunochemicals), followed by three washes as described above. The
last wash was done without T-20. Enzymatic activity was revealed with 15 mg of
3,39-diaminobenzidine tetrahydrochloride (Sigma Immunochemicals) in 30 ml of
TBS containing 15 ml of 30% H2O2.
Statistical analysis. All data comparisons were analyzed for statistical signif-
icance with the two-tailed paired Student t test. Differences were considered
significant at P , 0.05.
RESULTS
Specific antibody responses of antimony-resistant Indian
kala-azar patients. Five symptomatic kala-azar patients who
failed to respond to the conventional treatment with pentava-
FIG. 1. Levels of LAg-specific IgG (A), IgM (B), IgA (C), and IgE (D) in the sera of Indian kala-azar patients before treatment and following SAG unrespon-
siveness and cure. Symbols represent individual patients, and the same symbols indicating the same patients are used in Fig. 2. The heavy line represents the mean (6
standard error) of the Ig isotype level for five individuals.
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lent antimonials were retreated successfully with amphotericin
B. The serological profile of the Ig isotypes and IgG subclasses
in this group were studied at 0, 45, and 75 days posttreatment.
Major laboratory findings of this longitudinal study are shown
in Fig. 1 and 2 and Table 1. High titers of anti-LAg IgG
antibodies before the initiation of therapy were reduced insig-
nificantly (Fig. 1A; Table 1) after unsuccessful treatment with
SAG. Individually, three patients exhibited a decrease in the
IgG titers, whereas two showed an increase in the levels. After
successful cure with amphotericin B, however, the IgG anti-
bodies in all of the patients were significantly lowered, dem-
onstrating a 96% reduction in the levels in comparison to the
unresponsive state (P , 0.05). Despite the decrease, strong
IgG titers (1,350 6 969) persisted even after cure. In contrast,
very low levels of LAg-specific IgA isotypes were detected in
untreated VL patients, with almost no change after SAG and
amphotericin B treatment and after cure (Fig. 1C; Table 1).
Low levels of IgM observed during disease on average re-
mained constant after unsuccessful SAG treatment, although
some variation was observed from patient to patient. Following
treatment with amphotericin B, the IgM levels in all of the
patients were reduced, and the average reduction was statisti-
cally significant (Fig. 1B; Table 1). Levels of IgE observed
during disease remained almost constant after SAG treatment,
with only one patient showing a twofold increase in the titer
(Fig. 1D). After cure, however, a decrease in the level of IgE
FIG. 2. Specific IgG subclass levels in kala-azar patient sera before treatment and following SAG resistance and cure. The symbols and the heavy line are as
described for Fig. 1.
TABLE 1. Changes in LAg-specific mean IgG, IgM, IgA, and IgG
subclass levels in kala-azar patients following
drug resistance and cure
Isotype
% Reduction of level in:
SAG-resistant seraa
(45 days posttreat-
ment; n 5 5)
Sera after successful treatment
Amphotericin B cureb
(75 days posttreat-
ment; n 5 5)
SAG curea (50 days
posttreatment;
n 5 10)
IgG 4.8 96d 91f
IgM 1.8 88.5e 80e
IgA 19.5 29.1c 21.3c
IgE 6.6 92g 97h
IgG1 2123c,f 93.5h 90.6g
IgG2 46.5d 85 88.5f
IgG3 43d 94e 91g
IgG4 3 95h 91h
a Calculated as [(level before treatment) 2 (level after SAG treatment)] 3
100/(level before treatment).
b Calculated as [(level during SAG resistance) 2 (level after amphotericin B
cure)] 3 100/(level during SAG resistance).
c A negative value represents an increase.
d P , 0.05.
e P , 0.02.
f P , 0.01.
g P , 0.001.
h P ,, 0.001.
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was observed in all of the patient sera, and the percent reduc-
tion was most significant for IgE (P , 0.001) (Table 1) in
comparison with other Ig isotypes.
Analysis of the sera for their patterns of IgG subclass anti-
bodies reactive with LAg extracted from L. donovani revealed
significantly higher levels of IgG1 in comparison to IgG2,
IgG3, and IgG4 in untreated VL patients (P , 0.02) (Fig. 2).
After unsuccessful SAG treatment, IgG1 increased signifi-
cantly (P , 0.01), by 2.2-fold in comparison to the untreated
state. The increase in IgG1 titer was observed in all five indi-
vidual patients tested and reached almost equivalent levels
(Fig. 2A; Table 1). In contrast, the levels of IgG2 and IgG3
were reduced significantly (Fig. 2; Table 1). Of the five sera
tested, only one patient serum showed an increase in the IgG2
and IgG3 levels after SAG treatment. The anti-LAg IgG4
response, however, remained almost constant with antimony
therapy, showing minimal variation from patient to patient.
Following successful cure with amphotericin B, the levels of all
of the IgG subclasses were reduced significantly, with maxi-
mum declines in IgG3 and IgG4 antibodies (P ,, 0.001).
Nevertheless, significant LAg-specific IgG1 titers (606 6 499)
persisted in clinically cured individuals.
Serological responses of VL patients successfully cured with
SAG. Of the 15 patients investigated in this study, 10 re-
sponded to the standard regimen of antimony with good clin-
ical results and parasitological cures. As observed earlier, be-
fore treatment was started, all of the patients tested had strong
anti-LAg IgG antibodies. After cure, the level of IgG dropped
significantly in all of the patient sera (Fig. 3A; Table 1) but still
remained measurable (1,971 6 834). A significant fall in IgE
and IgM levels was also observed in all patients except one,
who showed an increase in IgM titer (Fig. 3B; Table 1) at the
end of treatment. In contrast, the comparatively lower level of
anti-LAg specific IgA remained steady before and after ther-
apy with SAG (Fig. 3C). Cure with antimony also corre-
sponded with the most significant decline (97%; P ,, 0.001)
in IgE antibodies.
Analysis of the IgG subclass antibodies of the paired pre-
and posttreatment serum samples of 10 patients successfully
cured with SAG revealed a significant decrease (P , 0.01) in
the titers of all of the IgG subclasses (Fig. 4; Table 1). This
decline, observed in all of the patients, was most significant for
IgG4 antibodies (P ,, 0.001). Low but significant IgG1 titers
(548 6 115) remained after cure.
Immunoblot analysis of L. donovani antigens reacting with
Indian kala-azar sera. Membrane antigens of L. donovani run
on sodium dodecyl sulfate-polyacrylamide gels were trans-
ferred to nitrocellulose for immunoblotting with pre- and post-
treatment kala-azar sera. Serum specimens from two patients,
one unresponsive to antimony and cured with amphotericin B
and the other successfully cured with SAG, were investigated
for their reactivity with LAg. Before therapy, both of the pa-
tients showed strong reactions with more than 17 antigenic
components ranging in molecular mass from 24 to 163 kDa
(Fig. 5, lanes 1 and 4). The major reactive components recog-
nized by these untreated samples were 130, 100, 72, 63, 52, 46,
39, 36, and 31 kDa. The serum specimen from the patient
unsuccessfully treated with SAG reacted with almost all of the
FIG. 3. LAg-specific IgG (A), IgM (B), IgA (C), and IgE (D) serum antibodies of kala-azar patients before and after SAG therapy. Symbols represent individual
patients, and the same symbols depict the same patients in Fig. 4. The heavy line represents the mean (6 standard error) of the Ig isotype level for 10 samples.
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antigenic components recognized before therapy but with an
overall lower intensity (Fig. 5, lane 2). After successful cure,
the major polypeptides recognized by both the sera (130, 72,
63, 46, and 36 kDa) were similar (Fig. 5, lanes 3 and 5) and
were fewer in number than the components of LAg reactive
with pretreatment sera. However, the extents of reactivity for
both of the serum specimens were variable.
DISCUSSION
Immunologic abnormalities and successful host defense in
VL have been shown to be associated with T-cell responses.
The detection of high titers of antileishmanial antibodies has
been exploited mainly for the development of serological tests
for diagnosis, and very little attention has been given to anal-
ysis of antibodies at the isotype and subclass levels in relation
to pathogenesis. Most of the serological assays developed so
far, however, fail to obviate the need for microscopy as the
“gold standard” for diagnosis. Based mainly on the detection
of IgG antibodies, these tests show cross-reactivity with other
pathogens, including those causing malaria, tuberculosis, or
leprosy, which are coendemic with kala-azar, and may remain
positive for cured VL sera for long periods of time (19, 22, 35,
38). In a recent report we have demonstrated the Ig subclass
distribution and the specificity of IgG3 for the diagnosis of
kala-azar (5). In the present study we report the differential
response of Ig subclass antibodies after successful chemother-
FIG. 4. IgG subclass antibody titers of Indian kala-azar patients before and after treatment with SAG. The symbols and the heavy line are as described for Fig. 3.
FIG. 5. Immunoblots of LAg with sera from untreated and cured kala-azar
patients. Lanes 1 to 3, reactivity with untreated, SAG-unresponsive, and ampho-
tericin B-cured sera of one kala-azar patient at 0, 45, and 75 days posttreatment,
respectively. Lanes 4 and 5, reactivity with untreated and SAG-cured sera of
another kala-azar patient at 0 and 50 days posttreatment, respectively. The
reactivities with the major bands are indicated on the right.
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apy and the distinct pattern for drug unresponsiveness in the
sera of Indian kala-azar patients.
Acute infection, as reported earlier (5), correlated with el-
evated levels of IgG, IgM, IgE, and IgG subclasses in both
SAG-responsive and unresponsive patients. Although some
differences in the levels of these isotypes were observed in the
two groups, the difference was statistically significant for only
IgG3 and IgG4, their titers being higher in the drug-resistant
group. Successful drug therapy demonstrated significant reduc-
tions in the levels of IgG, IgM, IgE, and all IgG subclasses in
both groups. This decrease in the antibody levels was observed
in all but one serum sample, for IgM. The orders for the
significance of reduction in the mean levels of antibody re-
sponses, however, were IgE . IgG . IgM . IgA and IgG4 .
IgG1 . IgG3 . IgG2 for the SAG-cured patients and IgE .
IgM . IgG . IgA and IgG1 . IgG4 . IgG3 . IgG2 for the
amphotericin B-treated individuals. This difference arose be-
cause of the change in the pattern of the isotypes following
unsuccessful SAG treatment. Antimony unresponsiveness in-
duced varying effects on the levels of IgG, IgA, IgG2, and IgG3
in the different patients, while the response was more consis-
tent for IgG1, IgG4, and IgE. Average titers revealed insignif-
icant changes in the levels of IgG, IgM, IgA, IgE, and IgG4 and
a significant decrease in the response of IgG2 and IgG3. The
most noticeable effect, however, was the increase in the titers
of IgG1 antibodies observed in all of the patients, rising to
almost equal levels. Although it is not understood how these
changes in the isotype patterns occur from pretreatment to
drug unresponsiveness or cure, it appears that the enhance-
ment of IgG1 after unsuccessful therapy may be a possible
marker for the identification of SAG resistance in VL patients.
Since almost all of the isotypes decrease markedly with reso-
lution of disease, the steady state of IgE, IgM, and IgG4 in
SAG-unresponsive sera may serve as additional markers for
drug resistance. Conversely, successful therapy could possibly
be monitored by the decline especially in IgE and IgG4 and
additionally in IgG1 in SAG-unresponsive amphotericin B-
treated individuals. These preliminary results are sufficiently
promising to warrant further validation to determine their po-
tential as markers in kala-azar.
Leishmania-specific elevations of IgG subclasses in VL pa-
tients have been reported for Somali, Sudanese, and Venezu-
elean populations. Similar to our observations, Venezuelan
and Somali patient sera had dominant IgG1 antibodies (41,
47). However, in Sudanese patients there was maximum gen-
eration of IgG3 and IgG4 production (18). Again, cure corre-
lated with a decrease in only IgG3 and IgG1 antibody titers in
the Sudanese patient sera. The discrepancies in these results
may be due partly to ethnic variation and differences in para-
sitic genotypes and partly to the specificities of the antibodies
for the antigens studied (21, 44). In order to identify the im-
munodominant leishmanial proteins in our antigen prepara-
tion and their involvement in the pathological consequences,
follow-up sera from two kala-azar patients were reacted with
immunoblots of LAg. Both of the acute-phase sera showed
similar reactivities to various leishmanial antigens. A number
of the major antigens recognized (130, 100, 72, 63, 52, 46, 39,
36, and 31 kDa) are expressed by different forms of leishman-
iasis (9, 12, 14, 30) and recognize VL sera from different
geographic regions (6, 23, 32, 33, 36, 38, 42). While SAG
resistance did not induce a major change in the antigenic
reactivity, sera obtained after successful therapy recognized
fewer bands in LAg. Of interest is the disappearance of the 39-
and 31-kDa antigens, which were found to be nonreactive in
cured kala-azar patients and asymptomatic subjects by other
workers (32, 43).
Since the immunologic mechanisms underlying the profound
stimulation of the specific Ig isotypes in patients with kala-azar
remain undefined, the modulation of their response with che-
motherapy also is not understood. Cytokines produced by
helper T cells have been implicated in the regulation of isotype
switching by activated B cells, and in mice IFN-g, preferentially
secreted by the Th1 subset, has been shown to stimulate the
production of complement-fixing IgG2a and IgG3 antibodies
(16, 45). The signature cytokines of Th2 cells, IL-4 and IL-5,
are recognized as helpers for B lymphocytes and stimulate the
production of high levels of IgE, IgM, and non-complement-
fixing IgG isotypes such as IgG1 in mice or its homologue IgG4
in humans (1, 39). In murine models of Leishmania infections,
a Th2–IL-4–IgG1 response has been associated with suscepti-
bility and a Th1–IFN-g–IgG2a response has been associated
with protective immunity (2, 3, 11). Similarly, significant stim-
ulation of IgM, IgE, and IgG4 in kala-azar patients may be
correlated with the elevation of a Th2 response. Simultaneous
elicitation of IgG1, IgG3, and IgG2, however, is difficult to
explain. Since IgG1 and IgG3 have the greater ability to fix
complement in humans and to mediate inflammatory reactions
(24), which is also the principal function of Th1 cells, elevation
of these isotypes may reflect the activity of the Th1 subset. The
occurrence of both Th1 and Th2 subsets of T-helper cells
during active VL has been well documented through the de-
tection of serum and lesional cytokines (20, 26, 46, 48). Since
a distinct pattern of cytokines has not been identified with drug
resistance and even after cure, assessment of the immune sta-
tus of patients through cytokine analysis is still not feasible (7,
27, 28). In contrast, a steady level of IgM, IgE, and IgG4
following unsuccessful drug therapy may be correlated with
disease persistence during clinical relapse. The increase in
IgG1 reflects its inability to down regulate the disease-promot-
ing effects of Th2 cells. Resolution of infection corresponds to
a decline most significantly of IgE and IgG4, which further
points to the significance of Th2 cells in the pathogenesis of
kala-azar and its regulation in the control of the disease.
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